Budesonide (targeted-release for primary IgA nephropathy)
Indication
Treating primary IgA nephropathy (NICE TA937)
NICE TA937 - Targeted-release budesonide for treating primary IgA nephropathy
Brand:
Kinpeygo
Nice TA:
937
Commissioning responsibility:
CCG
PbR excluded:
Yes
Background
1.1 Targeted-release budesonide is recommended as an option for treating primary immunoglobulin A nephropathy (IgAN) when there is a risk of rapid disease progression in adults with a urine protein-to-creatinine ratio of 1.5 g/g or more. Targeted-release budesonide is recommended only if:
it is an add-on to optimised standard care including the highest tolerated licensed dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), unless these are contraindicated
the company provides it according to the commercial arrangement.